Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
Top Cited Papers
- 31 August 2012
- journal article
- review article
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 12 (4), 464-470
- https://doi.org/10.1016/j.coph.2012.06.008
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- The genetic basis of early T-cell precursor acute lymphoblastic leukaemiaNature, 2012
- Antiangiogenic and Antimetastatic Activity of JAK Inhibitor AZD1480Cancer Research, 2011
- The Mutational Landscape of Head and Neck Squamous Cell CarcinomaScience, 2011
- STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumorsNature Medicine, 2010
- Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3Molecular Cancer Therapeutics, 2010
- The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid TumorsCancer Cell, 2009
- Janus kinases in immune cell signalingImmunological Reviews, 2009
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000